These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 31995015)
1. Martins MCMR; Pantaleao SQ; de Oliveira Almeida M; Weber KC; Honorio KM Med Chem; 2021; 17(3):247-263. PubMed ID: 31995015 [TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2 Musoev A; Numonov S; You Z; Gao H Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858 [TBL] [Abstract][Full Text] [Related]
3. Understanding the molecular dynamics of type-2 diabetes drug target DPP-4 and its interaction with Sitagliptin and inhibitor Diprotin-A. Chakraborty C; Hsu MJ; Agoramoorthy G Cell Biochem Biophys; 2014 Nov; 70(2):907-22. PubMed ID: 24809328 [TBL] [Abstract][Full Text] [Related]
4. Integrated Protocol to Design Potential Inhibitors of Dipeptidyl Peptidase- 4 (DPP-4). Pantaleão SQ; Philot EA; de Oliveira Almeida M; Lima AN; de Sairre MI; Scott AL; Honorio KM Curr Top Med Chem; 2020; 20(3):209-226. PubMed ID: 31878857 [TBL] [Abstract][Full Text] [Related]
5. Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation. Meduru H; Wang YT; Tsai JJ; Chen YC Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304951 [TBL] [Abstract][Full Text] [Related]
6. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120 [TBL] [Abstract][Full Text] [Related]
7. Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase IV inhibitors. Sharma M; Gupta M; Singh D; Kumar M; Kaur P Chem Biol Drug Des; 2012 Dec; 80(6):918-28. PubMed ID: 22943413 [TBL] [Abstract][Full Text] [Related]
8. Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents. Li G; Huan Y; Yuan B; Wang J; Jiang Q; Lin Z; Shen Z; Huang H Eur J Med Chem; 2016 Nov; 124():103-116. PubMed ID: 27560285 [TBL] [Abstract][Full Text] [Related]
9. Identification of levomenthol derivatives as potential dipeptidyl peptidase-4 inhibitors: a comparative study with gliptins. Alade AA; Ahmed SA; Mujwar S; Kikiowo B; Akinnusi PA; Olubode SO; Olufemi OM; Ohilebo AA J Biomol Struct Dyn; 2024 May; 42(8):4029-4047. PubMed ID: 37261796 [TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase IV Inhibitory activity of Terminalia arjuna attributes to its cardioprotective effects in experimental diabetes: In silico, in vitro and in vivo analyses. Mohanty IR; Borde M; Kumar C S; Maheshwari U Phytomedicine; 2019 Apr; 57():158-165. PubMed ID: 30668318 [TBL] [Abstract][Full Text] [Related]
11. Structure-based virtual screening of dipeptidyl peptidase 4 inhibitors and their in vitro analysis. Rahman SU; Ali HS; Jafari B; Zaib S; Hameed A; Al-Kahraman YMSA; Langer P; Iqbal J Comput Biol Chem; 2021 Apr; 91():107326. PubMed ID: 32739275 [TBL] [Abstract][Full Text] [Related]
12. An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides. Sivaraman SA; Sabareesh V Curr Protein Pept Sci; 2024; 25(4):267-285. PubMed ID: 38173201 [TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors. Li Q; Zhou M; Han L; Cao Q; Wang X; Zhao L; Zhou J; Zhang H Chem Biol Drug Des; 2015 Oct; 86(4):849-56. PubMed ID: 25787859 [TBL] [Abstract][Full Text] [Related]
14. Identification and molecular docking study of sugarcane leaf-derived compounds as potent dipeptidyl peptidase IV, α-glucosidase, and α-amylase inhibitors. Kan R; Ren P; Wu A; Tang Q; Kong B; Xue C J Sci Food Agric; 2023 Aug; 103(11):5388-5400. PubMed ID: 37038045 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors. Li Q; Han L; Zhang B; Zhou J; Zhang H Org Biomol Chem; 2016 Oct; 14(40):9598-9611. PubMed ID: 27714283 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor. Nojima H; Kanou K; Terashi G; Takeda-Shitaka M; Inoue G; Atsuda K; Itoh C; Iguchi C; Matsubara H BMC Struct Biol; 2016 Aug; 16():11. PubMed ID: 27491540 [TBL] [Abstract][Full Text] [Related]
17. DPP-IV Inhibitory Phenanthridines: Ligand, Structure-Based Design and Synthesis. Khalaf RA; Masalha D; Sabbah D Curr Comput Aided Drug Des; 2020; 16(3):295-307. PubMed ID: 30526469 [TBL] [Abstract][Full Text] [Related]
18. The Discovery and Characterization of a Potent DPP-IV Inhibitory Peptide from Oysters for the Treatment of Type 2 Diabetes Based on Computational and Experimental Studies. Chen Z; Su X; Cao W; Tan M; Zhu G; Gao J; Zhou L Mar Drugs; 2024 Aug; 22(8):. PubMed ID: 39195477 [TBL] [Abstract][Full Text] [Related]
19. Structural Dynamics of DPP-4 and Its Influence on the Projection of Bioactive Ligands. Pantaleão SQ; Philot EA; de Resende-Lara PT; Lima AN; Perahia D; Miteva MA; Scott AL; Honorio KM Molecules; 2018 Feb; 23(2):. PubMed ID: 29473857 [TBL] [Abstract][Full Text] [Related]
20. Critical Role of Dipeptidyl Peptidase IV: A Therapeutic Target for Diabetes and Cancer. De S; Banerjee S; Kumar SKA; Paira P Mini Rev Med Chem; 2019; 19(2):88-97. PubMed ID: 29692250 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]